MMF, a metabolite of an MS drug (DMF) has the ability to counteract two of the primary causes of progression in Parkinson's, inflammation and oxidative stress. It has already shown success in controlling these factors in mice with chemically-induced Parkinsonism. The researchers are moving toward a clinical trial. MMF, or a related drug, should be helpful for those in the earlier stages of the disease, who still have a reasonable number of functioning dopaminergic neurons:
"If we can catch them early enough, maybe we can slow the disease," Morgan said."If it can help give five to eight more years of improved quality of life that would be great for our patients."